Antibe Therapeutics Company Profile (CVE:ATE)

About Antibe Therapeutics

Antibe Therapeutics logoAntibe Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is focused on pain, inflammation and regenerative medicine. The Company's segments include Antibe Therapeutics, and Citagenix, which is a marketer and distributor of regenerative medicines serving the dental and orthopedic market places. The Company's drug design methodologies involve chemically linking a base drug to its hydrogen sulfide-releasing molecule. Its lead compound, ATB-346, combines hydrogen sulfide with naproxen, which is a non-steroidal anti-inflammatory drug (NSAID). The Company's other products include ATB-352, which is indicated for the treatment of severe acute pain, and ATB-340 is a Gastrointestinal (GI)-safe derivative of aspirin. The Company also offers regenerative medical devices, which include PentOS (CGX-283), CGX-227, CGX-443 and URIST (CGX-276), all of which target bone regeneration, and are indicated for oral and maxillofacial surgery.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: CVE
  • Symbol: ATE
  • CUSIP:
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $N/A
  • 200 Day Moving Average: $N/A
  • 52-Week Range: C$0.10 - C$0.27
  • Trailing P/E Ratio: N/A
  • P/E Growth: N/A
  • Market Cap: $N/A
  • Outstanding Shares: 93,190,000
Additional Links:

Analyst Ratings

Consensus Ratings for Antibe Therapeutics (CVE:ATE) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Antibe Therapeutics (CVE:ATE)
DateFirmActionRatingPrice TargetDetails
3/13/2015M PartnersReiterated RatingBuyView Rating Details
(Data available from 10/21/2014 forward)


Earnings History for Antibe Therapeutics (CVE:ATE)
No earnings announcements for this company have been tracked by


Earnings Estimates for Antibe Therapeutics (CVE:ATE)
Current Year EPS Consensus Estimate: $-0.10 EPS


Dividend History for Antibe Therapeutics (CVE:ATE)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Antibe Therapeutics (CVE:ATE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/29/2016Scott Wilson CurtisInsiderBuy19,500C$0.13C$2,535.00
3/28/2016Scott Wilson CurtisInsiderBuy30,500C$0.13C$3,965.00
(Data available from 1/1/2013 forward)


Latest Headlines for Antibe Therapeutics (CVE:ATE)
DateHeadline logoAntibe Therapeutics Confirms Non-Addictive Properties for Its Second Pipeline Drug, ATB-352, a Potent, Non-Addictive Pain-Killer (CVE:ATE) - October 17 at 8:27 AM logoAntibe Therapeutics Announces Launch of Strategic Growth Initiative in the U.S. Market for Dental Biologics (CVE:ATE) - October 11 at 3:41 PM logoAntibe Therapeutics, Inc. V.ATE (CVE:ATE) - October 4 at 8:26 AM
News IconATB-346 Shows Promising Results in Experimental Melanoma (CVE:ATE) - September 23 at 8:39 AM logoAntibe Therapeutics to Present at 2016 Rodman & Renshaw Global Investment Conference (CVE:ATE) - September 7 at 12:34 PM logoAntibe Therapeutics Reports Q1 2017 Interim Financial and Operating Results (CVE:ATE) - August 30 at 3:37 PM logoAntibe Therapeutics Announces the Launch of Neomem® FlexPlus, a High-Performance Barrier Membrane for Oral Surgery (CVE:ATE) - August 16 at 3:41 PM logoAntibe Therapeutics Announces Successful Phase 2 Trial of ATB-346 in Osteoarthritis (CVE:ATE) - August 8 at 8:25 AM logoAntibe Therapeutics Reports 2016 Year-End Financial and Operating Results (CVE:ATE) - July 29 at 9:05 PM logoAntibe Therapeutics Announces the Appointment of New Board Member and Provides Update on Phase 2 Trial of ATB-346 (CVE:ATE) - July 19 at 9:49 AM logoAntibe Therapeutics Completes Final Closing of Non-Brokered Private Placement Bringing Total Proceeds to $1,455,000 (CVE:ATE) - June 22 at 8:46 PM logoAntibe Therapeutics Raises $968,500 in First Tranche of Non-Brokered Private Placement (CVE:ATE) - June 10 at 9:28 PM logoAntibe Therapeutics Presenting Update on ATB-346 at International Hydrogen Sulfide Conference (CVE:ATE) - May 30 at 10:50 AM logoAntibe Therapeutics To Present At 2016 Bloom Burton & Co. Healthcare Investor Conference (CVE:ATE) - May 2 at 11:57 AM logoAntibe Therapeutics Announces the Launch of PentOS OI(TM) Putty, a High-Quality Bone Graft Substitute for Oral and Maxillofacial Surgery (CVE:ATE) - April 18 at 11:28 AM logoAntibe Therapeutics Announces the Launch of PentOS OI™ Putty, a High-Quality Bone Graft Substitute for Oral and Maxillofacial Surgery (CVE:ATE) - April 18 at 11:28 AM logoAntibe Therapeutics Announces Grant Of Stock Options (CVE:ATE) - March 10 at 10:03 AM logoAntibe Therapeutics' ATB-346 Receives Approval For Phase 2 Clinical Trial In Osteoarthritis Patients (CVE:ATE) - March 7 at 9:59 AM logoAntibe Therapeutics Receives Approval to Proceed to Phase 2 Clinical Trial (CVE:ATE) - March 5 at 9:38 AM logoAntibe Therapeutics Reports Q3 2016 Interim Financial And Operating Results (CVE:ATE) - February 29 at 9:58 PM logoProfound Preventative and Restorative Effects of ATB-346 in Mice with Genetic Predisposition to Intestinal Cancer (CVE:ATE) - February 25 at 9:36 AM logoAntibe Therapeutics Inc. (ATE.V) (CVE:ATE) - February 6 at 8:54 AM logoAntibe Therapeutics Closes Acquisition Of Minority Interest In Citagenix Inc. (CVE:ATE) - February 2 at 7:42 PM logoAntibe Therapeutics Announces Payment in Kind Election (CVE:ATE) - January 28 at 9:04 AM


Antibe Therapeutics (CVE:ATE) Chart for Friday, October, 21, 2016

Last Updated on 10/21/2016 by Staff